Greenwich Lifesciences 

Yahoo Finance • 12 days ago

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

STAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Tr... Full story

Yahoo Finance • last month

Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Tr... Full story

Yahoo Finance • 2 months ago

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-10... Full story

Yahoo Finance • 4 months ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

STAFFORD, Texas, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Tra... Full story

Yahoo Finance • 5 months ago

Wednesday Sector Leaders: Drugs, Biotechnology Stocks

In trading on Wednesday, drugs shares were relative leaders, up on the day by about 1.6%. Leading the group were shares of Omeros, up about 84.5% and shares of Dynavax Technologies up about 38.6% on the day. Also showing relative strengt... Full story

Yahoo Finance • 5 months ago

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Tra... Full story

Yahoo Finance • 5 months ago

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100... Full story

Yahoo Finance • 5 months ago

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01 

STAFFORD, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100... Full story

Yahoo Finance • 5 months ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100... Full story

Yahoo Finance • 6 months ago

Healthcare Rally: Pulmonx, UHS, And X4 Lead After-Hours Gains Amid Strategic Updates

(RTTNews) - Several healthcare and biotech stocks posted notable gains in after-hours trading on Monday, driven by earnings updates, executive appointments, and capital market activity. Pulmonx Corp. (LUNG) surged 33.33% to $2.08 as of 9:... Full story

Yahoo Finance • 7 months ago

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100... Full story

Yahoo Finance • 7 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100... Full story

Yahoo Finance • 7 months ago

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-10... Full story

Yahoo Finance • 8 months ago

Greenwich LifeSciences expands breast cancer trial to Ireland

[Female healthcare worker doing research in laboratory] * Greenwich LifeSciences (NASDAQ:GLSI [https://seekingalpha.com/symbol/GLSI]) said it has expanded its Phase III FLAMINGO-01 trial [https://seekingalpha.com/pr/20236617-greenwich-l... Full story

Yahoo Finance • 8 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-10... Full story

Yahoo Finance • 8 months ago

Greenwich LifeSciences soars on FDA Fast Track status for lead asset

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images Greenwich LifeSciences (NASDAQ:GLSI [https://seekingalpha.com/symbol/GLSI]) added ~32% in the premarket on Wednesday after the U.S. FD... Full story

Yahoo Finance • 8 months ago

Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation

STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-10... Full story

Yahoo Finance • 9 months ago

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100... Full story

Yahoo Finance • 9 months ago

Greenwich LifeSciences brings clinical trial management in-house

STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a $165 million market cap biotechnology company currently trading at $12.01, announced Tuesday it is building an internal clinical trial management team to oversee its Phase III... Full story

Yahoo Finance • 9 months ago

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100... Full story